Biopróteses aórticas porcinas, modelo convencional e sem suporte ("stentless"): estudo comparativo

Fantini, Fernando Antônio; Vrandecic, Mário Osvaldo; Filho, Bayard Gontijo; Oliveira, O Cesar de; Martins, I; Marinho, António; Oliveira, Marcelo H.; Oliveira, Carla de; Silva, João A. P.

doi:10.1590/s0102-76381998000300007

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…myocardial revascularization. This percentage corresponds to that described in the international literature for similar surgeries [17][18][19][20][21] .…”

Section: Resultssupporting

confidence: 76%

Tratamento cirúrgico das valvopatias aórticas com bioprótese de pericárdio bovino sem suporte: resultados imediatos

Araujo¹,

Gerola²,

Kin³

et al. 2006

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…myocardial revascularization. This percentage corresponds to that described in the international literature for similar surgeries [17][18][19][20][21] .…”

Section: Resultssupporting

confidence: 76%

Tratamento cirúrgico das valvopatias aórticas com bioprótese de pericárdio bovino sem suporte: resultados imediatos

Araujo¹,

Gerola²,

Kin³

et al. 2006

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…The improvement in the quality of life is set against its durability, which is the reason for several changes in the preparation of biological tissues and prosthesis projects [2][3][4][5]. The concept of bioprosthesis, introduced by Carpentier et al [6], allows favorable long-term results with heterologous prostheses manufactured from porcine aortic valves [7].…”

Section: Introductionmentioning

confidence: 99%

Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia

Bacco¹,

Sant'Anna²,

Sant’Anna³

et al. 2005

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Methods: From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean: 60.6 ± ± ± ± ± 14.3 years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival.Results: Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcific degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcific degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187): 82.0 ± ± ± ± ± 13.3% vs. 58.8 ± ± ± ± ± 13.6% in the 9 th year. Event-free survival was 77.5 ± ± ± ± ± 3.7% for 5 th year and 40.2 ± ± ± ± ± 9.0% for 10 th year. 424BACCO, FW ET AL -St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival Braz J Cardiovasc Surg 2005; 20(4): 423-431 Resultados: Em um seguimento total de 931,0 pacientesano, ocorreram 28 (9,2%) óbitos tardios, sendo cinco (1,6%) relacionados à bioprótese, sete (2,3%) cardíacos, quatro (1,3%) não-cardíacos e 12 (3,9%)

show abstract

“…Implantation of biological prosthesis during heart valve replacement reduces the risk of thromboembolic events and avoids specific anticoagulation therapy [1]. The improvement in the quality of life is set against its durability, which is the reason for several changes in the preparation of biological tissues and prosthesis projects [2][3][4][5]. The concept of bioprosthesis, introduced by Carpentier et al [6], allows favorable long-term results with heterologous prostheses manufactured from porcine aortic valves [7].…”

Section: Introductionmentioning

confidence: 99%

<![CDATA[St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival]]>

Bacco¹,

Sant'anna²,

Sant’Anna³

et al. 2005

Braz. j. cardiovasc. surg.

View full text Add to dashboard Cite

The objective of this work is to present longterm results of valve replacement using SJM-Biocor TM bovine pericardial bioprostheses. Methods: From 1992 to 2000, 304 patients were discharged from hospital after bioprosthesis implantation. Ages ranged from 15 to 83 years (mean: 60.6 ± ± ± ± ± 14.3 years) and 50.3% were male. Patient deaths and events related to bioprosthesis (infection, thromboembolism and structural failure) were considered for estimation of cumulative probability of survival and event-free survival. Results: Total follow-up was 931.0 patients-year. During follow-up there were 28 (9.2%) deaths. Causes were bioprosthesis failure in five (1.6%), cardiac in seven (2.3%), non-cardiac in four (1.3%), and unknown in 12 (3.9%) patients. Events related to bioprosthesis were: endocarditis: 18 (5.9%), fibrocalcific degeneration: 15 (4.9%), thromboembolism: three (1.0%), hemolysis: one (0.3%). Bioprosthesis dysfunctions resulted in 16 (5.2%) reoperations due to fibrocalcific degeneration (nine), endocarditis (six) and thromboembolism (one). Probability of survival was higher in the young population (< 40 years, n=35) when compared to the older group (> 60 year, n=187): 82.0 ± ± ± ± ± 13.3% vs. 58.8 ± ± ± ± ± 13.6% in the 9 th year. Event-free survival was 77.5 ± ± ± ± ± 3.7% for 5 th year and 40.2 ± ± ± ± ± 9.0% for 10 th year. Overall estimative of structural failure for a SJM-Biocor TM was 5% in 5 th year increasing to 20% in the 10 th year. In the aortic position the values were zero and 8%, respectively. Considering current clinical conditions, 88.5% are in NYHA class I, 9.1% in class II and 2.3% in class III. Conclusions: SJM-Biocor TM bovine pericardial bioprostheses resulted in satisfactory survival of patients, related to low prevalence of bioprosthesis dysfunction. Descriptors: Bioprosthesis. Heart valve prosthesis. Heart valves. Resumo Objetivo: Nosso objetivo é apresentar resultados a longo prazo da subsituição valvar por bioprótese de pericárdio bovino SJM-Biocor TM. Método: Entre 1992 e 2000, tiveram alta hospitalar, após substituição valvar por bioprótese de pericárdio bovino SJM-Biocor TM 304 pacientes. Idades eram de 15 a 83 anos (média: 60,6± ± ± ± ±14,3), sendo 50,3% do sexo masculino. Pacientes tiveram situação clínica atualizada e análise atuarial foi empregada no cálculo da sobrevida simples e livre de eventos.

show abstract

Biopróteses aórticas porcinas, modelo convencional e sem suporte ("stentless"): estudo comparativo

Cited by 6 publications

References 0 publications

Tratamento cirúrgico das valvopatias aórticas com bioprótese de pericárdio bovino sem suporte: resultados imediatos

Tratamento cirúrgico das valvopatias aórticas com bioprótese de pericárdio bovino sem suporte: resultados imediatos

Bioprótese valvar de pericárdio bovino St Jude Medical-Biocor: sobrevida tardia

<![CDATA[St Jude Medical-Biocor bovine pericardial bioprosthesis: long-term survival]]>

Contact Info

Product

Resources

About